Bristol -Myers Squibb recently announced that the data on a recent trial of a experimental immunotherapy for a certain type of lung cancer looks very promising. 1 year survival rates were as high as 41% vs. the typical 5.5-18%. Check out the article located at http://www.reuters.com/article/2014/10/30/us-bristol-myers-cancer-study-idUSKBN0IJ1KT20141030.

This makes me think of how many more drugs have come out in the past 20 years to treat different types of lung disease. We’ve come a long way from the days of just having albuterol updrafts and atrovent mdis!